Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7332440 | 0.85 | CYP3A4 (0.53) | EDNRAKMT2ACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL22404286 | 0.84 | EDNRA (0.56) | EDNRAKMT2ACYP3A4TAS1R3TAS1R1 | |
| SCHEMBL1746047 | 0.83 | PTGS2 (0.56) | EDNRAKMT2ATAS1R3TAS1R1HPGD | |
| SCHEMBL805660 | 0.83 | EDNRA (0.55) | EDNRAKMT2ACYP3A4TAS1R3TAS1R1 | |
| SCHEMBL14200154 | 0.83 | CYP3A4 (0.49) | KMT2ACYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL10204938 | 0.82 | EDNRA (0.54) | EDNRAKMT2ACYP3A4TAS1R3TAS1R1 | |
| SCHEMBL14032401 | 0.82 | EDNRA (0.54) | EDNRAKMT2ACYP3A4TAS1R3TAS1R1 | |
| SCHEMBL805662 | 0.82 | EDNRA (0.54) | EDNRAKMT2ACYP3A4TAS1R3TAS1R1 | |
| SCHEMBL7333176 | 0.81 | MAPK9 (0.55) | EDNRAKMT2ACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL12825470 | 0.81 | EDNRA (0.56) | EDNRAKMT2ATAS1R3TAS1R1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365093-B2 | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2008-04-29 | — | — | US | disclosed |
| US-20060229280-A1 | Endothelin antagonists | ABBVIE INC. | 2006-10-12 | — | — | US | disclosed |
| US-6946481-B1 | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2005-09-20 | — | — | US | disclosed |
| EP-0901470-B1 | INDOLE DERIVATIVES USEFUL AS ENDOTHELIN RECEPTOR ANTAGONISTS | PFIZER (US) | 2004-03-31 | — | — | EP | disclosed |
| CN-1384100-A | Benzo-1,3-dioxole and benzofuran substituted pentazane derivative | ABBOTT CO (US) | 2002-12-11 | — | — | CN | disclosed |
| CN-1091768-C | Novel benzo-1, 3-dioxolyl-and benzofuranyl-substituted pyrrolidine derivatives as endothelin antagonists | ABBOTT LAB CO (US) | 2002-10-02 | — | — | CN | disclosed |
| US-6384070-B2 | RESTENOSIS, KIDNEY DISEASES, LUNG DISEASES | PFIZER INC. | 2002-05-07 | — | — | US | disclosed |
| US-6306852-B1 | INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF A VARIETY OF DISEASES INCLUDING RESTENOSIS, RENAL FAILURE AND PULMONARY HYPERTENSION, AND TO PHARMACEUTICAL FORMULATIONS CONTAINING SUCH COMPOUNDS. | PFIZER INC. | 2001-10-23 | — | — | US | disclosed |
| US-20010014677-A1 | Restenosis, kidney diseases, lung diseases | RAWSON DAVID JAMES (GB) | 2001-08-16 | — | — | US | disclosed |
| US-6136843-A | CARDIOVASCULAR DISORDERS; KIDNEY DISORDERS | PFIZER INC (US) | 2000-10-24 | — | — | US | disclosed |
| WO-1996004905-A1 | PHENOXYPHENYLACETIC ACID DERIVATIVES | MERCK & CO., INC. (US) | 1996-02-22 | — | — | WO | disclosed |
| US-5401745-A | Cardiovascular disorders or hypotensive agents | MERCK & CO., INC. (US) | 1995-03-28 | — | — | US | disclosed |
| US-5391566-A | An endothelin antagonist, hypotensive agents, antiinflammatory agents for treating cardiovascular disorders, kidney disorders , brain disorders, asthma | MERCK & CO., INC. (US) | 1995-02-21 | — | — | US | disclosed |
| WO-1995003044-A1 | BENZIMIDAZOLINONES SUBSTITUTED WITH PHENOXYPHENYLACETIC ACID DERIVATIVES | MERCK & CO., INC. (US) | 1995-02-02 | — | — | WO | disclosed |
| WO-1994021255-A1 | SIX-MEMBERED RING FUSED IMIDAZOLES SUBSTITUTED WITH PHENOXYPHENYLACETIC ACID DERIVATIVES | MERCK & CO., INC. (US) | 1994-09-29 | — | — | WO | disclosed |
| WO-1994021259-A1 | QUINAZOLINONES SUBSTITUTED WITH PHENOXYPHENYLACETIC ACID DERIVATIVES | MERCK & CO., INC. (US) | 1994-09-29 | — | — | WO | disclosed |
| WO-1994021590-A1 | PHENOXYPHENYLACETIC ACID DERIVATIVES | MERCK & CO., INC. (US) | 1994-09-29 | — | — | WO | disclosed |
| EP-0617001-A1 | Phenoxyphenylacetic acid derivatives | MERCK & CO. INC. (US) | 1994-09-28 | — | — | EP | disclosed |
| US-5334598-A | Have endothelin antagonist activity; useful in treating cardiovascular disorders, hypertension, inflammatory diseases and asthma | MERCK & CO., INC. (US) | 1994-08-02 | — | — | US | disclosed |
| US-4435419-A | Method of treating depression using azabicyclohexanes | AMERICAN CYANAMID COMPANY (US) | 1984-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014677-A1 | Restenosis, kidney diseases, lung diseases | NR1H2, NR1H3, NR1H4 | EDNRA 102/4885KMT2A 3771/4885CYP3A4 1287/4885 |
| US-20060229280-A1 | Endothelin antagonists | EDNRA, EDNRB, ECE1 | EDNRA 1/4885KMT2A 3752/4885CYP3A4 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.